Related Experiment Video
Updated: Sep 27, 2026

COVID-19 Seroprevalence Test for IgG Antibody Levels Among Healthy Donors Across Different Pandemic Phases in Jeddah
Published on: June 24, 2025
Changes in Glycemic Control and Lipid Profiles Following COVID-19 Infection in Adults with Type 2 Diabetes: A
Yazeed Alshuweishi1, Jehad A Aldali2, Hamood Alsudais1
1Chair of Medical and Molecular Genetics Research, Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 12372, Saudi Arabia.
Abstract:
Background: The clinical course and mortality risk of COVID-19 in patients with type 2 diabetes (T2D) remain elevated. Understanding its pathogenesis is essential for prognostic and therapeutic strategies. Viral infections can disrupt host glucose and lipid metabolism. This study evaluated changes in glycemic and lipid parameters following COVID-19 infection in T2D patients. Methods: A retrospective analysis was conducted on T2D patients who tested positive for COVID-19 between April 2020 and December 2021. Laboratory results before and after infection were compared to assess changes in glycemic and lipid markers. Results: The study included 969 patients with T2D; 56.7% were female, and the median age was 58 years (IQR: 49-67). Hypertension, asthma, and chronic kidney disease were present in 51.5%, 14.2%, and 7.2% of patients, respectively. Fasting blood glucose did not change significantly from before to after COVID-19 infection [7.9 mmol/L (IQR: 6.2-10.6) vs. 7.8 mmol/L (IQR: 6.2-10.2)], nor did HbA1c [7.6% (IQR: 6.7-9.1) vs. 7.6% (IQR: 6.5-9.2)]. In contrast, modest but statistically significant reductions were observed in triglycerides [1.47 mmol/L (IQR: 1.13-2.00) vs. 1.44 mmol/L (IQR: 1.08-1.94)], total cholesterol [4.3 mmol/L (IQR: 3.67-5.03) vs. 4.1 mmol/L (IQR: 3.55-4.93)], and LDL cholesterol [2.7 mmol/L (IQR: 2.11-3.45) vs. 2.5 mmol/L (IQR: 1.98-3.23)]. HDL cholesterol remained unchanged [1.0 mmol/L (IQR: 0.90-1.21) vs. 1.0 mmol/L (IQR: 0.89-1.22)]. Conclusions: COVID-19 infection was not associated with significant long-term changes in glycemic control among patients with T2D, as fasting blood glucose and HbA1c levels remained broadly stable after infection. In contrast, significant reductions were observed in total cholesterol, LDL cholesterol, and triglyceride levels, while HDL cholesterol remained unchanged. These findings indicate that changes following COVID-19 infection were more apparent in lipid parameters than in glycemic markers.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type I Diabetes III: Clinical Manifestations
Diabetes: Symptoms, Diagnosis, and Complications
Type II Diabetes II: Pathophysiology
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...